Biologics in Asthma: Role of Biomarkers.
Lavoie G. and Pavord ID., (2024), Immunology and allergy clinics of North America, 44, 709 - 723
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.
Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice
Navigating uncertainty: asthma biologics during pregnancy.
Howell I. et al, (2024), The Lancet. Respiratory medicine
A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma.
Garcia G. et al, (2024), Advances in therapy
CHARACTERIZATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS IN THE CAPTAIN STUDY.
Oppenheimer J. et al, (2024), J Allergy Clin Immunol Pract
Blood eosinophils and lung function loss: from passive prediction to active prevention?
Ramakrishnan S. et al, (2024), European Respiratory Journal, 63, 2400812 - 2400812
The Rebirth of Lebrikizumab for Airway Disease.
Pavord ID., (2024), J Allergy Clin Immunol Pract, 12, 1225 - 1227
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A. et al, (2024), Respiratory medicine, 224
Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.
Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials.
van Dijkman SC. et al, (2024), Advances in therapy, 41, 1201 - 1225
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Russell RJ. et al, (2024), The European respiratory journal
Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease
Petousi N. et al, (2024), Thorax
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.
Pavord ID. et al, (2024), American journal of respiratory and critical care medicine
Pioneering a paradigm shift in asthma management: remission as a treatment goal.
Lommatzsch M. et al, (2024), The Lancet. Respiratory medicine, 12, 96 - 99
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
Bacharier LB. et al, (2024), The Journal of allergy and clinical immunology
From treatable traits to GETomics in airway disease: moving towards clinical practice.
Papi A. et al, (2024), European respiratory review : an official journal of the European Respiratory Society, 33
How have we measured trial outcomes of asthma attack treatment? A systematic review.
Howell I. et al, (2024), ERJ open research, 10, 660 - 2023
Fractional exhaled nitric oxide (FeNO): the future of asthma care?
Wang K. et al, (2023), The British journal of general practice : the journal of the Royal College of General Practitioners, 73, 565 - 568